A REVIEW ON NEWLY APPROVED ANTI CANCER DRUGS

T. M. Suneel Babu; Sourav De; Subhasis Banerjee

Authors

T. M. Suneel Babu Seven Hills College of Pharmacy, Tirupati, Andhra Pradesh.
Sourav De Assistant Professor, Department of Pharmaceutical Chemistry, Seven Hills College of Pharmacy, Tirupati, Andhra Pradesh.
Subhasis Banerjee Assistant Professor, Department of Pharmaceutical Chemistry, Gupta College of Technological Sciences, Asansol, West Bengal

Keywords:

Mutations, Alkylating agents, Monoclonal antibodies, FDA, Oncology, Myeloma, Lymphomas, and Neuroblastoma, non-small cell lung cancers (NSCLC)

Abstract

Cancer is most threatening disease posed to mankind. A lot of clinical, experimental research and epidemiological Studies have been carried out in the field of oncology so as to know the possible causes of cancer and mechanisms Involved in transformation of a normal cell into a neoplastic cell. Food and drug authority (U.S.F.D.A) approved several new and combination of anti cancer drugs in recent times. Approved drugs include alkylating agents, kinase inhibitors, human monoclonal antibodies, immunostimulatory antibodies, nucleoside metabolic inhibitors, epidermal growth factor receptor antagonist, alkylating agents. This review covers drug details that are approved by FDA in therapeutic areas of oncology.

Downloads

Download data is not yet available.

References

G.P.WARWICK, the Mechanism of Action of Alkylating Agents, 10.1200/JCO.2007.15.7438JCO April 10, 2008 vol. 26 no. 11, 1774-1777.

Natsuko Kondo et al, DNA Damage Induced by Alkylating Agents and Repair Pathways, Journal of Nucleic Acids Volume 2010 (2010), Article ID 543531, 7 pages. http://dx.doi.org/10.4061/2010/543531

C.Gridelli et al,Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel, Annals of Oncology 15: 419–426, 2004 Original article DOI: 10.1093/annonc/mdh087

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471934.htm

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036s000lbl.pdf

http://www.jnj.com/news/all/DARZALEX-daratumumab-Approved-by-US-FDA-First-Human-Anti-CD38-Monoclonal-Antibody-Available-for-the-Treatment-of-Multiple-Myeloma

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf

https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/farydak.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf

http://www.pfizer.com/news/press-release/press-release- detail/pfizer_receives_expanded_fda_approval_for_ibrance_palbociclib_in_hr_her2_metastatic_breast_cancer

http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469575.pdf.

http://www.amgen.com/media/news-releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us/

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205552s002lbl.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266s000lbl.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s012lbl.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf